[CAS NO. 2919019-72-8] ccc_R08
PRODUCTS SPECIFICATIONS [2919019-72-8]
DESCRIPTION [2919019-72-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 414.84 |
| Molecular Formula | C22H19ClO6 |
| SMILES | O=C1C=C(C2=CC=C(OCCOC3CC(C(O)=O)C3)C=C2)OC4=C1C=CC=C4Cl |
Summary
In Vitro
ccc_R08 (0.3, 1.0, 3.2, 10, 32 µM; 5 days) significantly reduces the level of cccDNA, protein-free RC-DNA, and double stranded linear DNA (DL-DNA) in HepDES19 cells
[1]
.
ccc_R08 (0-100 µM) dose-dependently reduces the level of extracellular HBeAg from HepDES19 cells, with IC
50
of ~0.1 µM
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | HepDES19 cells |
| Concentration: | 0.3, 1.0, 3.2, 10, 32 µM |
| Incubation Time: | 5 days |
| Result: | Reduced the level of cccDNA, protein-free RC-DNA, and double stranded linear DNA (DL-DNA). |
In Vivo
ccc_R08 (20 mg/kg; p.o.; twice per day for 2 weeks) clears cccDNA from the liver of HBVcircle mice
[1]
.
ccc_R08 (10, 15, 20, 30 mg/kg; p.o.; twice per day for 2 weeks) significantly decreases the serum level of pgRNA in a dose-dependent manner, and the reduction in pgRNA is quantitatively correlated with that in liver cccDNA at different doses
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | HBVcircle mouse model [1] . |
| Dosage: | 20 mg/kg |
| Administration: | Oral administration; twice per day for 2 weeks |
| Result: | Led to the clearance of cccDNA from HBVcircle mouse livers. |
| Animal Model: | HBVcircle mouse model [1] . |
| Dosage: | 10, 15, 20, 30 mg/kg |
| Administration: | Oral administration; twice per day for 42 days |
| Result: | Led to a sustained reduction in the serum levels of pgRNA. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References